...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Medical Virology >Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK
【24h】

Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK

机译：英国专家护理下慢性丙型肝炎患者的疗效和药物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Designing services with the capacity and expertise to meet the needs of the chronic hepatitis C (CHC) population in the era of direct acting antivirals (DAAs), and widening access to such treatments, requires detailed understanding of the characteristics and healthcare needs of the existing patient population. In this retrospective analysis of data from the National HCV Research UK Biobank between March 2012 and October 2014, the characteristics of the CHC population currently under specialist care in the UK were evaluated-with specific focus upon use of medications, adverse lifestyle choices, and comorbidities. Demographic data, risk factors for CHC acquisition, HCV genotype, liver disease status, lifestyle factors, comorbidities, and medication classes were collected. Data were analyzed by history of injecting drug use (IDU), age, and severity of liver disease. A total of 6278 patients (70.5% white; median age, 52 years) from 59 UK specialist centres were included; 59.1% of patients had acquired HCV through IDU. The prevalence of adverse lifestyle factors was significantly lower in non-IDU compared with previous IDU or recent IDU patients. Depression was common in the previous (50.8%) and recent IDU (68.1%) groups, compared with 27.6% in non-IDU patients. Cirrhosis was common (23.6%), and prevalence increased with age. We describe a heterogeneous, polymorbid, and aging population of CHC patients in secondary care, and demonstrate under representation of injecting drug users within the current system. The implications of this present significant challenges to physicians and healthcare commissioners in designing services which are fit for purpose in the DAA era.
机译：设计具有能力和专业知识的服务，以满足直接作用抗病毒药物（DAA）时代慢性丙型肝炎（CHC）人群的需求，并扩大此类治疗的使用范围，需要详细了解现有患者群体的特征和医疗需求。在对2012年3月至2014年10月英国国家HCV研究生物库数据的回顾性分析中，对英国目前接受专科护理的CHC人群的特征进行了评估，重点是药物使用、不良生活方式选择和共病。收集人口统计学数据、CHC获得的风险因素、HCV基因型、肝病状态、生活方式因素、共病和药物类别。数据按注射吸毒史（IDU）、年龄和肝病严重程度进行分析。共有来自59个英国专科中心的6278名患者（70.5%为白人；中位年龄52岁）被纳入研究；59.1%的患者通过注射吸毒获得HCV。非注射吸毒者不良生活方式因素的患病率明显低于既往注射吸毒者或近期注射吸毒者。在之前的注射吸毒组（50.8%）和最近的注射吸毒组（68.1%）中，抑郁症很常见，而在非注射吸毒组患者中，抑郁症的发生率为27.6%。肝硬化很常见（23.6%），患病率随年龄增长而增加。我们描述了二级护理中的CHC患者的异质性、多病态和老龄化人群，并证明在当前系统中注射吸毒者的代表性不足。这对医生和医疗保健专员在设计适合DAA时代目的的服务方面提出了重大挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号